<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00624858</url>
  </required_header>
  <id_info>
    <org_study_id>NB-402</org_study_id>
    <nct_id>NCT00624858</nct_id>
  </id_info>
  <brief_title>A Study of Naltrexone SR/ Bupropion SR in Overweight or Obese Subjects With Major Depression</brief_title>
  <official_title>An Open-Label Study Assessing the Safety and Efficacy of Naltrexone Sustained Release (SR)/Bupropion Sustained Release (SR) in Overweight or Obese Subjects With Major Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orexigen Therapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orexigen Therapeutics, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether a combination of naltrexone SR and
      bupropion SR is safe and effective in the treatment of major depression in overweight or
      obese subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the change in depressive symptoms as measured by Montgomery-Asberg Depression Rating Scale (MADRS) total score at 12 weeks</measure>
    <time_frame>12 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the percentage change from baseline in total body weight at 12 and 24 weeks.</measure>
    <time_frame>12 and 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>NB32</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naltrexone SR 32 mg/Bupropion SR 360 mg/ day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>naltrexone SR 32 mg/ bupropion SR 360 mg daily</intervention_name>
    <description>All subjects are to complete a 4 week titration period at which time subjects will be titrated up to a maintenance level of study drug. Subjects will then take the maintenance dose of study drug for an additional 20 weeks.
During the study, subjects will receive ancillary therapy including advice on diet and exercise</description>
    <arm_group_label>NB32</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female and male subjects must be 18 to 65 years of age;

          -  Have body mass index (BMI) greater or equal to 27 and less than or to equal 43kg/m2;

          -  Meet criteria for major depression

          -  Women of child-bearing potential, must be non-lactating and agree to use effective
             contraception throughout the study period and 30 days after discontinuation of study
             drug;

          -  Able to comply with all required study procedures and schedule;

          -  Able to speak and read English;

          -  Willing and able to give written informed consent

        Exclusion Criteria:

          -  Obesity of known endocrine origin

          -  Serious medical condition

          -  History of drug or alcohol abuse or dependence

          -  Use of excluded concomitant medications

          -  History of surgical or device (e.g. gastric banding) intervention for obesity;

          -  History or predisposition to seizures

          -  Pregnant or breast-feeding women or planning to become pregnant during the study
             period or within 30 days of discontinuing study drug;

          -  Planned surgical procedure that can impact the conduct of the study;

          -  Use of investigational drug, device or procedure within 30 days prior to Screening;

          -  Participation in any previous clinical trial conducted by Orexigen Therapeutics;

          -  Any condition which in the opinion of the investigator makes the subject unsuitable
             for inclusion in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan McElroy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lindner Center of HOPE</name>
      <address>
        <city>Mason</city>
        <state>Ohio</state>
        <zip>45040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2008</study_first_submitted>
  <study_first_submitted_qc>February 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2008</study_first_posted>
  <disposition_first_submitted>October 23, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>October 23, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 30, 2012</disposition_first_posted>
  <last_update_submitted>October 23, 2012</last_update_submitted>
  <last_update_submitted_qc>October 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>depressed</keyword>
  <keyword>overweight</keyword>
  <keyword>obese</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Overweight</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

